Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lipocine Inc. Director's Dealing 2022

Nov 8, 2022

35074_dirs_2022-11-08_6ed35b40-8921-4c2a-9a47-8845f78eba26.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lipocine Inc. (LPCN)
CIK: 0001535955
Period of Report: 2022-11-01

Reporting Person: Nomikos George (Chief Medical Officer)